"Country Doctor"
JOIN CDA NEWS INDEX POLITICS DISPENSING EDUCATION FEATURES BOOKS SMALL ADS GP FEES LIGHT BITES LINKS FEEDBACK
|
|
ProntodermÒ
washing solution brings MRSA decontamination efficacy and skin tolerance
to This
month, B. Braun Medical, the MRSA
is a bacteria that can be found harmlessly on the skin and nasal passage
of up to 50% of the population. The need for ProntodermÒ
is highlighted by the growing
prevalence of MRSA and the subsequent threat to those in hospital care.
Since mandatory recording of
blood born MRSA infections was introduced in The
ProntodermÒ
range contains a surfactant plus the
bactericide Polyhexanide, to which MRSA shows no resistance.
The specialised ProntodermÒ
range of anti-MRSA solutions are targeted for use, and have been shown
to be: ·
Suitable for long term use ·
Extremely tissue friendly ·
Dermatologically harmless ·
Easy to use as they require no rinsing Polyhexanide
has been used safely for years as a contact lens solution preservative,
as a disinfection agent in swimming pools and on Mainland Europe to
treat infected wounds and colonised skin. Results in As
a result, the author of the study, Prof HM Seipp of the Joanne
Clegg, Product Manager for disinfection and hygiene products at B. Braun
comments on the current situation in hospitals. ‘The problem develops
when a person with the MRSA strain of bacteria enters the hospital.
These people can act as carriers, bringing MRSA into a clinical setting.
MRSA is spread by hand-to-hand contact and can cause infection to others
and to the individual.’ ‘As
part of the battle to reduce MRSA infection, hospitals are increasingly
checking new patients to see if they carry the MRSA organism,’
explains Joanne. If they are found to be carriers, then the
patient will be ‘decolonised’ using washes for all the skin,
including hair, armpits, lower body and especially the nose where MRSA
tends to accumulate.’ The
ProntodermÒ
range is specifically designed for
ease of use making compliance with decontamination procedures easier for
medical professionals and patients. The ProntodermÒ
range includes the following products: ·
ProntodermÒ
Solution: Standard solution
for patient cleansing ·
ProntodermÒ
Concentrate: To be diluted ·
ProntodermÒ
Gel strong: For showering
·
ProntodermÒ
Gel light: For the nose ·
ProntOralÒ:
For gargling ·
ProntodermÒ
Foam: For cleansing B.
Braun has extensively tested the products in vitro and on carriers of
MRSA. The product is also tried and tested in The
Department of Health advises that patients shown to carry MRSA who are
due to under go high risk procedures, such as elective orthopaedic or
cardiovascular surgery, are recommended to perform whole body
decontamination with skin and nose treatment prior to surgery. For
further information, please contact: References: Notes Many
S. aureus have developed resistance to a range of antibiotics.
Methicillin-resistance S. aureus is resistant to most antibiotics and is
therefore difficult to erradicate. About
30 per cent of the general population carries S. aureus; in hospital the
percentage is higher. S. aureus carriage is more likely to be MRSA in
hospital populations (patients and staff) than in the community. Carriage
sites are nose (most common) and skin, especially skin folds such as
axilla (armpit) or groin. A carrier can be a source of infection for
themselves (e.g. if they have a wound) or others. B.
Braun B.
Braun offers healthcare professionals and hospitals an outstanding range
of products, from our world renowned surgical instruments to our
innovative implants and therapeutic systems, all matched by a
comprehensive range of high quality services. Polihexanide The
compound is well tolerated by the human skin, because it is attracted to
the acidic lipids of bacterial cell membranes, while human cell
membranes are largely neutral. -------------------------------------------------------------- Silver
Fabric Can Help Hospitals Meet Cleanliness Targets |
|
